5-Amino-1MQ vs GLP-1 (7-37)

Inhibits NNMT enzyme, increasing SAM (S-adenosylmethionine) availability. Alters adipocyte gene expression to reduce fat cell size and may increase brown adipose tissue activity via epigenetic mechanisms.

A small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor that reduces adipocyte differentiation and promotes metabolic shifts in fat cells. Not a true peptide — a synthetic quinolinium compound frequently sold alongside peptide protocols by online vendors.

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

The active endogenous form of glucagon-like peptide-1, an incretin hormone released from intestinal L-cells after eating. The mechanistic basis for the GLP-1 receptor agonist drug class (semaglutide, liraglutide). Studied for glucose regulation and appetite suppression.